ClinicalTrials.gg
CompletedNCT00171704Updated Mar 3, 2017Results posted

A Study to Evaluate the Effect of Letrozole and Tamoxifen on Bone and Lipids in Postmenopausal Women With Breast Cancer

A Phase 3 interventional study of Letrozole and Tamoxifen in Hormone Sensitive Resected Primary Breast Cancer in Postmenopausal Women, sponsored by Novartis Pharmaceuticals. Completed at 13 sites in 2 countries. Open to female participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2017-03-03.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
263
Allocation
Randomized
Ages
50 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 162 studies testing letrozole in Breast Neoplasms — 22 open to participants now, 39 under way, 11 of them phase 3. Letrozole · Breast Neoplasms.

Enrollment
38th of 159
263 · median 95
Started
2005
with 10 others
Phase 3
41 of 162
4 open now
Registered
16th of 162
by date
Lead sponsor
21 of 162
Novartis Pharmaceuticals

Among the 162 studies testing letrozole in Breast Neoplasms, this one is the 38th largest by enrollment of the 159 interventional ones that give a count, is one of 11 that started in 2005, is one of 41 in phase 3, and was the 16th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

22 of the 162 studies testing letrozole in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

17 more — sign in →

By country, each count listing its studies:

All 22 open studies →

About letrozole

Letrozole: first FDA approval 1997 (FEMARA). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 50 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 162 studies testing letrozole in Breast Neoplasms, or all of them as a file.
02

Study summary

Estrogen is known to be a regulator of bone and lipid metabolism. Letrozole is a potent inhibitor of estrogen synthesis.

This study evaluated the effects of letrozole and tamoxifen on bone and lipid metabolism in postmenopausal women with resected, receptor positive early breast cancer.

03

Conditions studied

  • Hormone Sensitive Resected Primary Breast Cancer in Postmenopausal Women

Browse trials for

Keywords

  • Breast Cancer
  • Letrozole
  • Bone Mineral Density
  • Bone Markers
  • Serum lipid
  • Postmenopausal
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female
  • hormone status defined as:
  • Patients with menostasis (amenorrhea) > 12 months or history of oophorectomy.
  • Patients ≥ 55 years with history of hysterectomy or having continued/renewed menstruation on cyclic hormone treatment.
  • Patients of 50-54 years: Menopausal status was determined on the basis of follicle-stimulating hormone (FSH)/luteinizing hormone (LH) values.
  • confirmed resected breast cancer and eligible for endocrine therapy. As a minimum, patients had to have receptor-positive tumors, which were defined either as estrogen receptor (ER) and/or progesterone receptor (PgR) ≥ 10 fmol/mg cytosol protein; or ≥ 10% of the tumor cells positive by immunocytochemical evaluation.
  • Adequate bone marrow function (white blood cell count [WBC] > 3.0 x 109 /L, ≥ 100.0 x 109 /L, and > 10 g/dL).
  • Documented evidence of adequate renal function (creatinine \< 180 µmol/L) and hepatic function ( \< 30 µmol/L, (ALT) \< 1.5 x upper normal limit of the laboratory).
  • of at least 24 months at the time of enrollment.
  • Written voluntary prior to initiation of any study procedure.
  • Willingness to undergo all scheduled tests and examinations for evaluation of bone density and bone metabolism, and lipid profiles in addition to the standard assessments for monitoring their breast cancer status.

Exclusion criteria

Exclusion Criteria

  • Patients with distant as defined by the criteria of the Danish Breast Cancer Co-operative Group (DBCCOG).
  • Pre-existing bone disease (e.g. osteomalacia, osteogenesis imperfecta, Paget's disease).
  • Patients receiving bisphosphonates for more than 3 months before randomization.
  • Chronic treatment with drugs known to interfere with bone metabolism, e.g.
  • Anti-convulsants within the past year.
  • at doses greater than the equivalent of 5 mg/day prednisone for more than two weeks in the past 6 months (prior to randomization).
  • Any previous treatment with sodium fluoride at daily doses ≥ 5 mg/day for a period exceeding 1 month.
  • Anabolic steroids in the past 12 months.
  • Long term use of coumarin derivatives and heparin at the time of randomization.
  • Metabolic diseases known to interfere with bone metabolism (e.g., Hyperparathyroidism, hypoparathyroidism, uncontrolled thyroid disease, Cushing's disease, vitamin D deficiency, malabsorption syndrome, etc.).
  • Treatment with lipid-lowering agents within the 3 months prior to randomization (this exclusion criterion did not apply to patients randomized in the United Kingdom).
  • Patients receiving other anti-cancer treatment.
  • Previous / adjuvant chemotherapy and /or previous adjuvant endocrine therapy (e.g., anti-estrogens, AIs).
  • History of previous or concomitant within the past 5 years other than adequately treated basal or squamous cell carcinoma of the skin or in situ carcinoma of the cervix. Patients who had a previous other malignancy must have been disease free for five years. Patients with endometrial cancer and/or invasive breast cancer at any time in their medical history were excluded. Patients with invasive bilateral breast cancer were excluded. Patients with vaginal discharge/ vaginal bleeding with evidence of malignancy were excluded.
  • Any other non-malignant systemic diseases (cardiovascular, renal, hepatic, lung embolism, etc.) which would prevent prolonged follow-up.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
263 participants (actual)

Study arms

  • Experimental
    Letrozole

    2.5 mg once daily (q.d.)orally for 5 years

    Drug: Letrozole

  • Experimental
    Tam-Let

    20 mg Tamoxifen once daily (q.d.) orally for 2 years followed by Letrozole 2.5 mg q.d. orally for 3 years.

    Drug: Letrozole · Drug: Tamoxifen

Interventions

  • 2.5 mg tablets and supplied in bottles with 6-monthly supplies.

  • 20 mg tablets in bottles as 6-monthly supplies (supplied to Novartis as Tamofen from Schering Oy, Subsidiary of Schering AG, Pansiontie 47, FIN-2010 Turku, Finland)

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline of Bone Mineral Density of the Lumbar Spine (L2-l4)

    Lumbar spine (L2-L4) BMD measurements by dual energy X-ray absorptiometry (DXA) were performed after surgery and within 2 weeks prior to randomization and repeated every 6 months for the first 2 years and annually thereafter until 5 years after enrollment. The primary scanning site was the lumbar spine (L2 to L4) and the secondary scanning site was the total hip. All DXA scans were evaluated by a central reader.

    Time frame: Baseline, 24 months

Secondary outcomes

  1. Percent Change From Baseline of Bone Mineral Density of the Lumbar Spine

    Lumbar spine (L2-L4)BMD measurements by dual energy X-ray absorptiometry (DXA) were performed after surgery and within 2 weeks prior to randomization and repeated every 6 months for the first 2 years and annually thereafter until 5 years after enrollment. The primary scanning site was the lumbar spine (L2 to L4) and the secondary scanning site was the total hip. All DXA scans were evaluated by a central reader.

    Time frame: Baseline, 60 months

  2. Percent Change From Baseline of Bone Mineral Density (BMD) of Total Hip

    Total hip BMD measurements by dual energy X-ray absorptiometry (DXA) were performed after surgery and within 2 weeks prior to randomization and repeated every 6 months for the first 2 years and annually thereafter until 5 years after enrollment. All DXA scans were evaluated by a central reader.

    Time frame: Baseline, 60 months

  3. Median Percent Change From Baseline of Serum Markers of Bone Turnover

    Bone turnover markers (fasting serum procollagen-I extension peptide \[P1NP\], C-telopeptide \[CTX\], skeletal bone-specific alkaline phosphatase \[BSAP, N-telopeptide \[NTX\]) were measured at baseline/screening and at each visit thereafter. A central laboratory was used to analyze the samples. The analysis of bone markers was based on analysis of variance of the regression slopes calculated for each individual patient and each bone marker over time. In the following summary, only the median treatment group percent change from baseline (and range) at 5 years is presented for each bone marker.

    Time frame: Baseline, 60 months

  4. Percentage Change From Baseline in Serum Lipids at 5 Years

    Serum lipid profile (fasting serum cholesterol \[total, HDL and calculated LDL\], triglycerides, and lipoprotein \[a\]) were measured at baseline/screening and at each visit thereafter. A central laboratory was used to analyze the samples. The analysis of serum lipids was on the treatment group median percent change from baseline (and range) at 5 years.

    Time frame: Baseline, 60 months

  5. Number of Participants With Clinically Relevant Changes From Baseline in Cholesterol

    Serum lipid profile (fasting serum cholesterol \[total, HDL and calculated LDL\], triglycerides, and lipoprotein \[a\]) were measured at baseline/screening and at each visit thereafter. A central laboratory was used to analyze the samples. Numbers are not additive, as patients could be included in multiple rows.

    Time frame: Baseline, 60 months

  6. Time to Disease Recurrence or Death

    Disease-free survival was defined as the interval between randomization and earliest confirmed event of loco-regional recurrence, distant metastases, invasive contralateral breast cancer, or death from any cause.

    Time frame: 60 months

  7. Time to Overall Survival Events

    Overall survival was measured from date of randomization to date of death.

    Time frame: 60 Months

07

Results

Posted Jun 4, 2012
Limitations and caveats
The study was designed to investigate the effects of letrozole compared with tamoxifen for 2 years on BMD spine (L2-L4). The study was too small to investigate the comparative efficacy of treatments on disease-free survival or on overall survival.

Participant flow

Participant flow — Overall Study
MilestoneLetrozoleTam-Let
Started133130
Completed8981
Not completed4449
Withdrew: Adverse event2433
Withdrew: Disease progression149
Withdrew: New therapy for 2nd non-breast prim canc10
Withdrew: Administrative problems21
Withdrew: Death22
Withdrew: Withdrawal by subject13
Withdrew: Protocol violation01

Outcome measures

PrimaryPercent Change From Baseline of Bone Mineral Density of the Lumbar Spine (L2-l4)

Lumbar spine (L2-L4) BMD measurements by dual energy X-ray absorptiometry (DXA) were performed after surgery and within 2 weeks prior to randomization and repeated every 6 months for the first 2 years and annually thereafter until 5 years after enrollment. The primary scanning site was the lumbar spine (L2 to L4) and the secondary scanning site was the total hip. All DXA scans were evaluated by a central reader.

Time frame:
Baseline, 24 months
Reported as:
Median · Percent Change
Percent Change From Baseline of Bone Mineral Density of the Lumbar Spine (L2-l4)
Percent ChangeLetrozoleTam-Let
Percent Change From Baseline of Bone Mineral Density of the Lumbar Spine (L2-l4)-4.63 (-14.21 to 4.32)0.37 (-6.98 to 15.21)
SecondaryPercent Change From Baseline of Bone Mineral Density of the Lumbar Spine

Lumbar spine (L2-L4)BMD measurements by dual energy X-ray absorptiometry (DXA) were performed after surgery and within 2 weeks prior to randomization and repeated every 6 months for the first 2 years and annually thereafter until 5 years after enrollment. The primary scanning site was the lumbar spine (L2 to L4) and the secondary scanning site was the total hip. All DXA scans were evaluated by a central reader.

Time frame:
Baseline, 60 months
Reported as:
Median · Percent change
Percent Change From Baseline of Bone Mineral Density of the Lumbar Spine
Percent changeLetrozoleTam-Let
Percent Change From Baseline of Bone Mineral Density of the Lumbar Spine-5.66 (-15.06 to 5.11)-3.3 (-13.48 to 4.92)
SecondaryPercent Change From Baseline of Bone Mineral Density (BMD) of Total Hip

Total hip BMD measurements by dual energy X-ray absorptiometry (DXA) were performed after surgery and within 2 weeks prior to randomization and repeated every 6 months for the first 2 years and annually thereafter until 5 years after enrollment. All DXA scans were evaluated by a central reader.

Time frame:
Baseline, 60 months
Reported as:
Median · Percent Change
Percent Change From Baseline of Bone Mineral Density (BMD) of Total Hip
Percent ChangeLetrozoleTam-Let
Percent Change From Baseline of Bone Mineral Density (BMD) of Total Hip-5.77 (-22.53 to 12.53)-3.98 (-13.6 to 5.57)
SecondaryMedian Percent Change From Baseline of Serum Markers of Bone Turnover

Bone turnover markers (fasting serum procollagen-I extension peptide \[P1NP\], C-telopeptide \[CTX\], skeletal bone-specific alkaline phosphatase \[BSAP, N-telopeptide \[NTX\]) were measured at baseline/screening and at each visit thereafter. A central laboratory was used to analyze the samples. The analysis of bone markers was based on analysis of variance of the regression slopes calculated for each individual patient and each bone marker over time. In the following summary, only the median treatment group percent change from baseline (and range) at 5 years is presented for each bone marker.

Time frame:
Baseline, 60 months
Reported as:
Median · Percent Change
Median Percent Change From Baseline of Serum Markers of Bone Turnover
Percent ChangeLetrozoleTam-Let
Procollagen-I (PINP) (n=86, 78)-14.15 (-78.5 to 177.8)-0.5 (-84.8 to 200)
Bone Specific alkaline Phosphatase (n=87,78)16.2 (-53.6 to 192.6)19.15 (-58.00 to 237.8)
C-telopeptide (CTX) (n=88, 78)-12.05 (-80.9 to 130.6)4.55 (-81.2 to 236.8)
N-telopeptide (NTX) (n=-88, 77)-53.05 (-86.3 to 20.2)-50.7 (-100 to 39)
SecondaryPercentage Change From Baseline in Serum Lipids at 5 Years

Serum lipid profile (fasting serum cholesterol \[total, HDL and calculated LDL\], triglycerides, and lipoprotein \[a\]) were measured at baseline/screening and at each visit thereafter. A central laboratory was used to analyze the samples. The analysis of serum lipids was on the treatment group median percent change from baseline (and range) at 5 years.

Time frame:
Baseline, 60 months
Reported as:
Median · Percent Change
Percentage Change From Baseline in Serum Lipids at 5 Years
Percent ChangeLetrozoleTam-Let
Total Cholesterol (n=91, 82)-7.3 ± 17.64-2.45 ± 16.63
LDL Cholesterol (n=91, 82)-12.7 ± 24.947-11.05 ± 23.958
HDL Cholesterol (n=91, 82)8.7 ± 16.3888.9 ± -38.5
SecondaryNumber of Participants With Clinically Relevant Changes From Baseline in Cholesterol

Serum lipid profile (fasting serum cholesterol \[total, HDL and calculated LDL\], triglycerides, and lipoprotein \[a\]) were measured at baseline/screening and at each visit thereafter. A central laboratory was used to analyze the samples. Numbers are not additive, as patients could be included in multiple rows.

Time frame:
Baseline, 60 months
Reported as:
Number · Participants
Number of Participants With Clinically Relevant Changes From Baseline in Cholesterol
ParticipantsLetrozoleTam-Let
Patients with one or more change3021
≥8 mmol/L total (T) cholesterol75
≥7 mmol/L T.choles. & ≥1 risk for cardiac disease1812
≥6 mmol/L T. choles. & ≥2 risk for cardiac disease119
SecondaryTime to Disease Recurrence or Death

Disease-free survival was defined as the interval between randomization and earliest confirmed event of loco-regional recurrence, distant metastases, invasive contralateral breast cancer, or death from any cause.

Time frame:
60 months
Reported as:
Median · Days
Time to Disease Recurrence or Death
DaysLetrozoleTam-Let
Time to Disease Recurrence or DeathNA (NA to NA)NA (NA to NA)
SecondaryTime to Overall Survival Events

Overall survival was measured from date of randomization to date of death.

Time frame:
60 Months
Reported as:
Median · days
Time to Overall Survival Events
daysLetrozoleTam-Let
Time to Overall Survival EventsNA (NA to NA)NA (NA to NA)

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Letrozole—50/133 (37.6%)113/133 (85%)
Tam-Let—41/130 (31.5%)110/130 (84.6%)
Most frequent serious events
Showing 10 of 97
Most frequent serious events
EventLetrozoleTam-Let
OsteoarthritisMusculoskeletal and connective tissue disorders5/1334/130
PneumoniaInfections and infestations4/1331/130
DiverticulitisInfections and infestations3/1330/130
Metastases to boneNeoplasms benign, malignant and unspecified (incl cysts and polyps)3/1330/130
Acute myocardial infarctionCardiac disorders0/1332/130
Atrial fibrillationCardiac disorders2/1332/130
Breast infectionInfections and infestations0/1332/130
ErysipelasInfections and infestations1/1332/130
ArthralgiaMusculoskeletal and connective tissue disorders0/1332/130
Pain in extremityMusculoskeletal and connective tissue disorders0/1332/130
Most frequent other events
Showing 10 of 26
Most frequent other events
EventLetrozoleTam-Let
ArthralgiaMusculoskeletal and connective tissue disorders44/13343/130
Back painMusculoskeletal and connective tissue disorders14/13325/130
HypertensionVascular disorders25/13317/130
HypercholesterolaemiaMetabolism and nutrition disorders23/13321/130
OsteoporosisMusculoskeletal and connective tissue disorders21/1338/130
Hot flushVascular disorders13/13318/130
Oedema peripheralGeneral disorders17/13315/130
Bone painMusculoskeletal and connective tissue disorders16/13310/130
FatigueGeneral disorders7/13315/130
OsteopeniaMusculoskeletal and connective tissue disorders15/13312/130

Baseline characteristics

Age, Continuous
Age, Continuous(years)LetrozoleTam-LetTotal
Mean61.4 ± 6.161.8 ± 6.261.6 ± 6.2
Sex: Female, Male
Sex: Female, Male(Participants)LetrozoleTam-LetTotal
Female133130263
Male000
08

Study locations

13 sites
  • Novartis Investigative Site
    Aalborg, Denmark
  • Novartis Investigative Site
    Arhus, Denmark
  • Novartis Investigative Site
    Copenhagen, Denmark
  • Novartis Investigative Site
    Esbjerg, Denmark
  • Novartis Investigative Site
    Herlev, Denmark
  • Novartis Investigative Site
    Herning, Denmark
  • Novartis Investigative Site
    Hillerod, Denmark
  • Novartis Investigative Site
    Kløvervænget, Denmark
  • Novartis Investigative Site
    Roskilde, Denmark
  • Novartis Investigative Site
    Sonderborg, Denmark
  • Novartis Investigative Site
    Vejle, Denmark
  • Novartis Investigative Site
    Viborg, Denmark
  • Novartis Investigative Site
    Sheffield, United Kingdom
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2005, a primary completion of Mar 2011 and a completion of Mar 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2012, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 13, 2005
First posted
Sep 15, 2005
Start
Apr 2005
Primary completionActual
Mar 2011
CompletionActual
Mar 2011
Results first posted
Jun 4, 2012
Last update
Mar 3, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 3, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00171704
Collaborators
Danish Breast Cancer Cooperative Group, University of Sheffield
Responsible party
Sponsor
First posted
Sep 15, 2005
Start date
Apr 2005
Primary completion
Mar 2011
Completion
Mar 2011
Results posted
Jun 4, 2012
Last update
Mar 3, 2017

Study contacts

Novartis
study chair · Novartis
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Letrozole

Start the discussion